CINCINNATI , Aug. 07, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the fiscal third quarter ended June 30, 2020 . Third Quarter Fiscal 2020 Highlights: Consolidated Net Revenue of $84.8 million , up 75% year-over-year Life Science segment

CINCINNATI , July 28, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) announces the appointment of Anthony Bihl III to its Board of Directors, effective immediately. “We welcome Tony to the board as a new independent director and look forward to the leadership he will bring,” said

CINCINNATI , July 16, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, will report third quarter 2020 financial results Friday, August 7, 2020 . Jack Kenny , Chief Executive Officer, and Bryan Baldasare ,

CINCINNATI , July 13, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading provider of diagnostic testing solutions and life science raw materials, announced today that it has launched a high-sensitivity SARS-CoV-2 nucleocapsid antibody pair for the development of rapid

CINCINNATI , May 29, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) announced today that Jack Kenny , Chief Executive Officer, and Bryan Baldasare , Executive Vice President and Chief Financial Officer, will participate in a virtual fireside chat at the 40 th Annual William Blair

CINCINNATI , May 26, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading provider of diagnostic testing solutions and life science raw materials, announced today that its SARS-CoV-2 antigens and related reagents are part of assays granted U.S.

CINCINNATI , May 20, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience , Inc.’s (NASDAQ: VIVO) Board of Directors announced that Tony Serafini-Lamanna has been promoted to Executive Vice President of Diagnostics.  Jack Kenny remains Chief Executive Officer of Meridian, while passing responsibility of

CINCINNATI , May 08, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the second quarter ended March 31, 2020 . Second Quarter Fiscal 2020 Highlights: Consolidated Net Revenue of $57.3 million , up 14% year-over-year Life Science segment

CINCINNATI , May 06, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading provider of diagnostic testing solutions and life science raw materials, is pleased to announce its collaboration with QuantuMDx on its newly launched SARS-CoV-2 assay for laboratory use.  The

CINCINNATI , April 30, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, has completed its previously announced acquisition of Exalenz Bioscience Ltd., the Modiin, Israel based provider of the BreathID ®